Plus Therapeutics has successfully dosed 18 patients in the ReSPECT-LM Phase 1 trial, which focuses on the treatment of leptomeningeal metastases (LM) from solid tumors using rhenium (186Re) obisbemeda.

The Data Safety Monitoring Board (DSMB) has reviewed the safety of SON-080 in the Phase 1b part of Sonnet's clinical trial.

Nurix Therapeutics has received a boost as the FDA lifted a partial clinical hold on their Phase 1a/1b study of NX-2127.

Synnovation Therapeutics has announced the commencement of dosing for the first patient in their Phase I clinical trial of SNV1521, a PARP1 inhibitor, in patients with solid tumors.

Imugene Limited has announced the successful completion of the initial phase of its OASIS clinical trial.

Eilean Therapeutics LLC announced that its Australian subsidiary has received approval from the Human Research Ethics Committee to begin a Phase 1 clinical trial of balamenib (ZE63-0302).

Regulus Therapeutics has reported promising outcomes from the second group of participants in a Phase 1b clinical trial for a new drug, RGLS8429.

The trial is assessing the efficacy of KVA12123, a VISTA-blocking immunotherapy, both as a standalone treatment and in conjunction with Merck’s KEYTRUDA® (pembrolizumab).

Roche has recently announced at an online investor event that their experimental drug for Alzheimer's disease, trontinemab.

The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD).

Lineage Cell Therapeutics, has announced the upcoming presentation of two-year outcomes from a Phase 1/2a study of RG6501, also known as OpRegen.

In Durham, N.C., Atsena Therapeutics announced that the second group in their LIGHTHOUSE study has started receiving doses of ATSN-201.